Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Endocrinology

Symptoms and Look-Alikes: Identifying Your Type of PA

At a Glance

Familial hyperaldosteronism type II usually cannot be distinguished from sporadic primary aldosteronism by symptoms alone. Earlier high blood pressure, a family history of early stroke or heart attack, and genetic testing for CLCN2 help identify FH-II and guide family screening and treatment.

While the “red flag” emergencies previously discussed are rare, the daily reality of Primary Aldosteronism (PA) involves a set of core symptoms that can significantly impact your quality of life [1]. Most cases of PA are “sporadic,” meaning they happen by chance, but in some families, the condition is inherited. Because the symptoms of sporadic PA and the four familial types (FH-I through FH-IV) overlap, doctors use biochemical testing, genetics, and family history—not just symptoms—to tell them apart [2][3].

Core Symptoms of Hyperaldosteronism

Regardless of whether your PA is sporadic or familial, the excess hormone aldosterone forces your kidneys to hold onto salt and water while flushing out potassium [4]. This can lead to several common, though non-specific, symptoms:

  • Hypertension (High Blood Pressure): This is the most common feature. It is often “resistant,” meaning it doesn’t respond well to standard blood pressure medications [5].
  • Hypokalemia (Low Potassium): Although only a minority of patients have low potassium on a blood test, those who do may feel weak or have muscle cramps [6][7].
  • Nocturia (Nighttime Urination): Excess aldosterone interferes with the kidney’s ability to concentrate urine, leading to frequent trips to the bathroom at night [1].
  • Fatigue and Brain Fog: Many patients report a deep sense of exhaustion or difficulty concentrating [1].

Note: These symptoms are not diagnostic. You cannot tell what type of PA you have—or even if you have PA at all—based purely on symptoms, as things like fatigue and nocturia can be caused by sleep disorders, diabetes, or medications. Some patients with PA have no symptoms at all other than high blood pressure.

The “Look-Alikes”: Comparing PA Types

While you may feel similar symptoms in any version of PA, the underlying genetic “engine” driving the disease differs. The following are reported patterns, not absolute rules.

Type Genetic Cause Reported Clinical Patterns
Sporadic PA Usually not inherited Often diagnosed in adults; no strong family history of early stroke or PA [8][9].
FH Type I CYP11B1/B2 fusion Also called Glucocorticoid-Remediable Aldosteronism (GRA). It is unique because aldosterone production is driven by ACTH, meaning it can be treated with low-dose steroids (glucocorticoids) [10][2].
FH Type II CLCN2 gene variants Clinically similar to sporadic PA. It is usually distinguished by finding the pathogenic variant in the family and often appears at a younger age [11][12].
FH Type III KCNJ5 gene variants Often a more severe form. Frequently associated with early-onset, extreme high blood pressure, noticeably enlarged adrenals, and dangerously low potassium [2][13][14].
FH Type IV CACNA1H gene variants Usually appears in childhood, but severity is variable, sometimes presenting with normal potassium levels [3][15].

Why the Distinction Matters

It is important to understand that FH-II—the focus of your diagnosis—is primarily distinguished by your age of onset, family history, and genetic testing [2]. You cannot “feel” the difference between FH-II and sporadic PA because the lab results and symptoms are often identical [12].

Identifying a familial type through genetic testing is critical for two main reasons:

  1. Targeted Treatment: For example, a confirmed genetic diagnosis of FH-I can be treated with low-dose steroids [10]. FH-III is often resistant to medications and sometimes requires the surgical removal of both adrenal glands as a last-resort option [13]. CLCN2-associated FH-II is typically bilateral and managed with medications.
  2. Protecting Your Family: If you carry a pathogenic FH variant, your relatives may be at risk. Early screening through a genetic counselor can prevent the heart and kidney damage that occurs when high blood pressure goes untreated for decades [16][17].

If you were diagnosed with high blood pressure before age 35, or if you have a relative who had a stroke at a young age, your care team may suggest a multigene panel to determine if your “look-alike” symptoms are actually an inherited form of the disease [2][3].

Common questions in this guide

Can symptoms alone show that I have familial hyperaldosteronism type II?
No. FH-II and sporadic primary aldosteronism can both cause high blood pressure, low potassium, nighttime urination, fatigue, or muscle symptoms, and some people have no symptoms beyond high blood pressure. Doctors use blood tests, family history, and genetic testing to distinguish them.
Why might my doctor suspect familial hyperaldosteronism type II?
FH-II may be considered when primary aldosteronism or difficult-to-control high blood pressure begins at a young age, especially if relatives had primary aldosteronism or a stroke or heart attack early in life. These clues do not prove FH-II; a pathogenic CLCN2 variant helps confirm the inherited cause.
What does genetic testing add when my symptoms look like primary aldosteronism?
A familial hyperaldosteronism multigene panel can look for variants linked to the different familial types, including CLCN2. Genetic counseling helps explain the result and determine whether relatives may need blood pressure or primary aldosteronism screening.
Should my children or siblings be screened if I have FH-II?
A confirmed pathogenic familial hyperaldosteronism variant can mean biological relatives are at increased risk. Ask a genetic counselor about targeted testing and appropriate screening for high blood pressure or primary aldosteronism; the plan depends on the family result and each relative’s age and health.
How is FH-II usually treated compared with other familial types?
CLCN2-associated FH-II is typically bilateral and managed with medications to control aldosterone-related effects and blood pressure. Treatment differs among familial types: FH-I may respond to low-dose glucocorticoids, whereas severe FH-III can be resistant to medication and may rarely require removal of both adrenal glands.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Familial hyperaldosteronism type II.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my age of onset, which specific type of familial hyperaldosteronism (FH) should we investigate first?
  2. 2.Is a familial hyperaldosteronism multigene panel and genetic counseling indicated for me?
  3. 3.Are my potassium levels or imaging results suspicious for the KCNJ5 mutations seen in FH Type III?
  4. 4.Should my children or siblings be screened for high blood pressure or primary aldosteronism based on my results?
  5. 5.How does a genetic diagnosis of FH change my long-term medical or surgical treatment plan compared to sporadic PA?

References

References (17)
  1. 1

    Normotensive hypokalemic primary hyperaldosteronism mimicking clinical features of anorexia nervosa in a young patient: A case report.

    Huang YC, Tsai MH, Fang YW, Tu ML

    Medicine 2020; (99(29)):e20826 doi:10.1097/MD.0000000000020826.

    PMID: 32702825
  2. 2

    Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism.

    Araujo-Castro M, Parra P, Martín Rojas-Marcos P, et al.

    Frontiers in endocrinology 2024; (15()):1336306 doi:10.3389/fendo.2024.1336306.

    PMID: 38495792
  3. 3

    SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism.

    Zennaro MC, Jeunemaitre X

    Annales d'endocrinologie 2016; (77(3)):214-9.

    PMID: 27315758
  4. 4

    Inappropriately normal aldosterone levels as the norm for hyperaldosteronism: Use of a modified aldosterone-to-renin ratio to enhance primary aldosteronism detection.

    Bauzon J, Romero-Velez G, Perez-Soto R, et al.

    Surgery 2026; (198()):110473 doi:10.1016/j.surg.2026.110473.

    PMID: 42580016
  5. 5

    Autonomous Aldosterone Secretion as a Subclinical Form of Primary Aldosteronism: Pathogenesis and Clinical Significance.

    Kmieć P, Sworczak K

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2022; (130(1)):7-16 doi:10.1055/a-1556-7784.

    PMID: 34614533
  6. 6

    Hypokalemia and the Prevalence of Primary Aldosteronism.

    Gruber S, Beuschlein F

    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2020; (52(6)):347-356 doi:10.1055/a-1134-4980.

    PMID: 32252108
  7. 7

    Hypokalemic rhabdomyolysis: a rare manifestation of primary aldosteronism.

    Zavatto A, Concistrè A, Marinelli C, et al.

    European review for medical and pharmacological sciences 2015; (19(20)):3910-6.

    PMID: 26531278
  8. 8

    Primary aldosteronism diagnostics: KCNJ5 mutations and hybrid steroid synthesis in aldosterone-producing adenomas.

    Rege J, Turcu AF, Rainey WE

    Gland surgery 2020; (9(1)):3-13 doi:10.21037/gs.2019.10.22.

    PMID: 32206594
  9. 9

    Molecular mechanisms in primary aldosteronism

    De Sousa K, Abdellatif AB, El Zein RM, Zennaro MC

    Journal of molecular endocrinology 2019; (242(3)):R67-R79 doi:10.1530/JOE-19-0193.

    PMID: 31397984
  10. 10

    Role of ACTH and Other Hormones in the Regulation of Aldosterone Production in Primary Aldosteronism.

    El Ghorayeb N, Bourdeau I, Lacroix A

    Frontiers in endocrinology 2016; (7()):72 doi:10.3389/fendo.2016.00072.

    PMID: 27445975
  11. 11

    CLCN2 chloride channel mutations in familial hyperaldosteronism type II.

    Scholl UI, Stölting G, Schewe J, et al.

    Nature genetics 2018; (50(3)):349-354 doi:10.1038/s41588-018-0048-5.

    PMID: 29403011
  12. 12

    Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels.

    Stowasser M, Wolley M, Wu A, et al.

    Current hypertension reports 2019; (21(4)):31 doi:10.1007/s11906-019-0934-y.

    PMID: 30949771
  13. 13

    Familial hyperaldosteronism type III.

    Monticone S, Tetti M, Burrello J, et al.

    Journal of human hypertension 2017; (31(12)):776-781 doi:10.1038/jhh.2017.34.

    PMID: 28447626
  14. 14

    Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3.

    Gomez-Sanchez CE, Qi X, Gomez-Sanchez EP, et al.

    Molecular and cellular endocrinology 2017; (439()):74-80 doi:10.1016/j.mce.2016.10.025.

    PMID: 27793677
  15. 15

    Familial Hyperaldosteronism Type IV (FH-IV)-Clinical Phenotypes, Genetics and Management of CACNA1H-Related Primary Aldosteronism: A Systematic Review.

    Michalski W, Jaszczyszyn I, Bielska W, Stolarczyk A

    Journal of clinical medicine 2026; (15(10)) doi:10.3390/jcm15103693.

    PMID: 42194655
  16. 16

    Aldosterone and Cardiovascular Risk Across the Lifespan.

    Ananda RA, Mori TA, Yang J

    Metabolites 2025; (15(8)) doi:10.3390/metabo15080553.

    PMID: 40863169
  17. 17

    Subclinical Primary Aldosteronism and eGFR Decline Over Time.

    Hundemer GL, Desbiens LC, Agharazii M, et al.

    Journal of the American Society of Nephrology : JASN 2026; (37(8)):1754-1763 doi:10.1681/ASN.0000001039.

    PMID: 41686513

This page is for informational purposes only and does not constitute medical advice about familial hyperaldosteronism type II. Your clinician and genetic counselor should interpret your symptoms, laboratory results, imaging, and family history.